ALXN

Alexion Pharmaceuticals Stock Price

119.67
0.00 (0.0%)
119.67
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Alexion Pharmaceuticals Inc ALXN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 119.67 04:47:58
Close Price Low Price High Price Open Price Previous Close
119.67
Bid Price Ask Price Spread News
119.68 122.26 2.58 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 119.67 USD

Alexion Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 26.23B 219.17M 210.38M $ 4.99B $ 442.21M 10.71 31.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 1.20%

more financials information »

Alexion Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALXN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week120.975126.72118.18122.092,181,439-1.30-1.08%
1 Month111.19128.57109.93120.092,378,2058.487.63%
3 Months103.88128.5799.91113.392,160,35315.7915.2%
6 Months104.00128.5794.82110.912,056,77015.6715.07%
1 Year101.00128.5772.67105.322,100,55818.6718.49%
3 Years138.48142.2472.67113.361,872,145-18.81-13.58%
5 Years169.00193.4572.67120.611,896,458-49.33-29.19%

Alexion Pharmaceuticals Description

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.